Cantor Fitzgerald Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $215

Benzinga Newsdesk www.benzinga.com Positive 85.8%

Neg 0% Neu 0% Pos 85.8%

Cantor Fitzgerald analyst Josh Schimmer maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $210 to $215.